Selected article for: "time function and treatment group"
Author: Ni, Chenlu; Masters, Joe; Zhu, Ling; Yu, Weifeng; Jiao, Yingfu; Yang, Yuting; Cui, Cui; Yin, Suqing; Yang, Liqun; Qi, Bo; Ma, Daqing
Title: Study design of the DAS-OLT trial: a randomized controlled trial to evaluate the impact of dexmedetomidine on early allograft dysfunction following liver transplantation
  • Cord-id: o0yxnzzv
  • Document date: 2020_6_26
    • ID: o0yxnzzv
    Snippet: BACKGROUND: Perioperative ischemia/reperfusion (I/R) injury during liver transplantation is strongly associated with early allograft dysfunction (EAD), graft loss, and mortality. Hepatic I/R injury also causes remote damage to other organs including the renal and pulmonary systems. Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist which is used as an adjuvant to general anesthesia, has been shown in preclinical studies to provide organ protection by ameliorating the effects of I/R inju
    Document: BACKGROUND: Perioperative ischemia/reperfusion (I/R) injury during liver transplantation is strongly associated with early allograft dysfunction (EAD), graft loss, and mortality. Hepatic I/R injury also causes remote damage to other organs including the renal and pulmonary systems. Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist which is used as an adjuvant to general anesthesia, has been shown in preclinical studies to provide organ protection by ameliorating the effects of I/R injury in a range of tissues (including the liver). However, prospective clinical evidence of any potential benefits in improving outcomes in liver transplantation is lacking. This study aimed to verify the hypothesis that the application of dexmedetomidine during the perioperative period of liver transplantation can reduce the incidence of EAD and primary graft non-function (PNF). At the same time, the effects of dexmedetomidine application on perioperative renal function and lung function were studied. METHODS: This is a prospective, single-center, randomized, parallel-group study. Two hundred participants (18–65 years) scheduled to undergo liver transplantation under general anesthesia will be included in this study. For participants in the treatment group, a loading dose of DEX will be given after induction of anesthesia (1 μg/kg over 10 min) followed by a continuous infusion (0.5 μg/kg /h) until the end of surgery. For participants in the placebo group, an equal volume loading dose of 0.9% saline will be given after the induction of anesthesia followed by an equal volume continuous infusion until the end of surgery. All other supplements, e.g., opioids, sedatives, and muscle relaxant, will be identical in both arms and administered according to routine clinical practice. DISCUSSION: The present trial will examine whether DEX confers organoprotective effects in the liver, in terms of reducing the incidence of EAD and PNF in orthotopic liver transplantation recipients. TRIAL REGISTRATION: ClinicalTrials.gov NCT03770130. Registered on 10 December 2018. https://clinicaltrials.gov/ct2/show/NCT03770130

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute ards respiratory distress syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and liver function test: 1, 2
    • acute ards respiratory distress syndrome and liver tissue: 1, 2, 3
    • acute ards respiratory distress syndrome and liver tissue heart: 1, 2
    • acute ards respiratory distress syndrome and liver tissue heart brain lung: 1
    • acute ards respiratory distress syndrome and liver tissue heart brain lung kidney: 1
    • acute ards respiratory distress syndrome and liver transplant: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and liver transplant center: 1
    • acute ards respiratory distress syndrome and liver transplant surgery: 1
    • acute ards respiratory distress syndrome and liver transplantation: 1, 2, 3
    • acute ards respiratory distress syndrome and liver transplantation perioperative period: 1
    • acute ards respiratory distress syndrome and loading dose: 1
    • acute ards respiratory distress syndrome and local hospital: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and long term survival: 1, 2
    • acute ards respiratory distress syndrome and lt patient: 1
    • acute ards respiratory distress syndrome and lung alveolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
    • acute ards respiratory distress syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
    • acute ards respiratory distress syndrome and lung injury ameliorate: 1, 2, 3, 4, 5